View Post

Foscarnet prophylaxis reduces severity but does not prevent HHV-6 encephalitis

In All, Encephalitis & Encephalopathy, Transplant Complications, Treatments - Antiviral by Kristin Loomis

A Japanese trial of foscarnet prophylaxis in cord blood transplant patients was successful in reducing severity and mortality as well as suppressing high viral loads, but it failed to prevent encephalitis. The authors note that the blood brain barrier must be inflamed to allow effective penetration of the drug into the central nervous system and speculate that the prophylaxis may have protected the meninges.

View Post

HHV-6B reactivates first, proceeds to end organ disease faster in transplant patients

In All, Gastrointestinal, Transplant Complications by Kristin Loomis

Investigators at Fred Hutch Cancer Research Center found that HHV-6B is the first DNA virus to reactivate at a median of 3 weeks, compared to CMV, EBV and Adenovirus at 5-6 weeks. HHV-6B also peaked rapidly, unlike other DNA viruses that took 3-6 weeks to reach peak viral load. HHV-6B reactivation resulted in increased mortality after 100 days.